Link-Asia International Medtech Group Ltd. (1143) AI Stock Analysis

• Market Cap: HK$88.59M
• Dividend Yield: N/A
• Average Volume (3M): 1.35M
• Price to Earnings (P/E): 11.9
• Beta (1Y): 0.63
• Revenue Growth: -4.52%
• EPS Growth: 55.30%
• Country: HK
• Employees: 835
• Sector: Technology
• Sector Strength: 87
• Industry: Consumer Electronics
• EPS (TTM): 0.05
• Shares Outstanding: 224,289,180
• 10 Day Avg. Volume: 1,424,891
• 30 Day Avg. Volume: 1,353,783
• PEG Ratio: 0.47
• Price to Book (P/B): 0.15
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -8.10
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 60 Neutral
• Price Target: HK$0.50 ▲(25.00%Upside)

Link-Asia International Medtech Group Ltd. has a balanced stock score driven by technical analysis and valuation. The stock's upward momentum and fair valuation are positive, but financial performance challenges, particularly in revenue consistency and cash flow, limit the score.

Link-Asia International Medtech Group Ltd. Business Overview & Revenue Model

Company Description

Link-Asia International MedTech Group Limited, an investment holding company, provides electronic manufacturing services (EMS) for the telecommunications, security, car electronics, home appliances, other consumer, and industrial electronic products. The company operates through four segments: EMS, Distribution of Communications Products, Securities and Other Assets Investment, and Real Estate Supply Chain Services. It is also involved in the trade of personal care products, business telephone systems, and telecommunication products; manufacture and sale of telecommunications and other products, and consumable electronic products; sale of audio equipment; and provision of consultancy services, as well as pre-pregnancy care and assisted reproductive services. In addition, the company offers equity investment and property agency services; and real estate advisory and purchase services. It operates in the People's Republic of China, the United States, Switzerland, France, Poland, the United Kingdom, Belgium, Russia, Thailand, Malaysia, Brazil, and internationally. The company was formerly known as Link-Asia International Co. Ltd. and changed its name to Link-Asia International MedTech Group Limited in December 2020. Link-Asia International MedTech Group Limited was founded in 1992 and is headquartered in Tsim Sha Tsui, Hong Kong.

How the Company Makes Money

Link-Asia International MedTech Group Ltd. generates revenue primarily through the sale of its medical devices and healthcare solutions. The company likely engages in partnerships with healthcare providers, hospitals, and clinics to distribute its products. Revenue streams may include direct sales, long-term supply agreements, and possibly service contracts for maintenance and support of their medical technology. The company's earnings are influenced by factors such as product innovation, market demand, regulatory approvals, and its ability to establish and maintain strong relationships with key stakeholders in the healthcare industry.

Link-Asia International Medtech Group Ltd. Financial Statement Overview

Summary

Link-Asia International Medtech Group Ltd. shows mixed financial performance. While there is stability in equity and improved EBIT margin in 2024, challenges remain in revenue consistency and cash flow management, raising concerns about profitability and liquidity.

Income Statement

Link-Asia International Medtech Group Ltd. has shown mixed results over recent years. The company experienced declining revenues with a negative growth trend from 2019 to 2024, particularly from 2021 to 2024. While gross profit margins remained relatively stable, net profit margins were volatile, indicating potential profitability issues. The positive EBIT margin in 2024 is a welcome improvement, although historical EBIT margins were negative.

Balance Sheet

The company's balance sheet reveals a stable equity position with a moderate debt-to-equity ratio, indicating a balanced capital structure. The equity ratio has improved over time, suggesting a strengthening financial foundation. However, the fluctuating total debt and liabilities pose potential risks to financial stability.

Cash Flow

Cash flow analysis indicates inconsistent cash flow management. Operating cash flow was negative in several years, impacting free cash flow generation. Though there was a significant improvement in free cash flow in 2022, the lack of consistent positive cash flow raises concerns about long-term liquidity.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	479.32M	502.00M	529.25M	675.52M	595.02M
Gross Profit	123.60M	136.87M	101.40M	144.89M	154.71M
EBITDA	4.78M	40.49M	-14.06M	-4.54M	-116.52M
Net Income	8.04M	5.26M	-54.04M	-46.40M	-173.05M
Balance Sheet
Total Assets	880.14M	776.42M	659.23M	677.98M	657.40M
Cash, Cash Equivalents and Short-Term Investments	312.05M	271.57M	252.21M	146.80M	167.66M
Total Debt	86.60M	26.75M	51.08M	61.20M	70.19M
Total Liabilities	343.25M	287.69M	297.22M	311.98M	361.47M
Stockholders Equity	536.53M	486.66M	359.86M	365.88M	295.46M
Cash Flow
Free Cash Flow	-75.67M	-132.09M	99.60M	-122.55M	-45.85M
Operating Cash Flow	-73.19M	-129.29M	107.55M	-100.45M	-15.04M
Investing Cash Flow	49.83M	39.98M	-547.00K	3.31M	-96.19M
Financing Cash Flow	66.31M	101.84M	2.20M	74.19M	35.17M

Link-Asia International Medtech Group Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1143, the sentiment is Positive. The current price of 0.4 is above the 20-day moving average (MA) of 0.37, above the 50-day MA of 0.32, and below the 200-day MA of 0.59, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 65.59 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1143.

Link-Asia International Medtech Group Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	69 Neutral	¥228.59B	14.33	7.64%	2.71%	9.13%	8.49%
1143	60 Neutral	HK$88.59M	11.87	1.60%	―	-4.52%	55.30%
0328	32 Underperform	HK$46.40M	―		―	-8.62%	-151.60%
FTQ0		€4.20M	―	-213.23%	―	―	―
M2E			―		―	―	―
UPZ			―		―	―	―
8147	45 Neutral	HK$48.35M	23.77		―	9.61%	―

Link-Asia International Medtech Group Ltd. Corporate Events

Link-Asia International Medtech Group Ltd. Announces New Share Placing

Link-Asia International Medtech Group Ltd. has announced a placing agreement to issue up to 44,856,000 new shares, representing about 20% of its current share capital, at a price of HK$0.33 per share. This move is expected to raise approximately HK$14.5 million in net proceeds, which the company plans to use for acquiring energy storage products. The shares will be placed with at least six independent third-party investors, and the transaction is subject to certain conditions being met, indicating potential implications for the company’s financial strategy and market positioning.

China Energy Storage Technology Development Limited Rescinds Board Lot Size Change

China Energy Storage Technology Development Limited announced the lapse of its proposed change in board lot size, which was initially intended to increase from 4,000 shares to 8,000 shares. This decision follows the lapse of the Rights Issue, indicating a strategic shift that may impact the company’s market operations and investor relations.

China Energy Storage Technology Development Ltd. AGM Resolutions Passed Unanimously

China Energy Storage Technology Development Limited, formerly known as Link-Asia International MedTech Group Ltd., held its annual general meeting on June 20, 2025, where all proposed resolutions were passed unanimously. The resolutions included the adoption of audited accounts, reappointment of auditors, re-election of directors, and granting of mandates to the board for issuing and repurchasing shares. This unanimous approval reflects strong shareholder confidence in the company’s leadership and strategic direction.

China Energy Storage Technology Development Limited Announces Lapse of Major Transaction and Rights Issue

China Energy Storage Technology Development Limited, formerly known as Link-Asia International MedTech Group Ltd., announced the lapse of a major transaction and a proposed rights issue. The company stated that the conditions for both the Assignment and the Rights Issue could not be fulfilled by their respective deadlines, leading to their termination. Despite these lapses, the company does not foresee any material adverse effects on its financial position and plans to explore other business or fundraising opportunities to improve its financial standing.

China Energy Storage Technology Development Updates on Proposed Transactions

China Energy Storage Technology Development Limited, formerly known as Link-Asia International MedTech Group Ltd., is involved in the energy storage technology sector. The company has announced updates regarding its proposed rights issue, change in board lot size, and a major transaction related to the assignment of distribution rights. The company is still in negotiations to amend the terms of these proposed transactions and has not yet decided whether to proceed. Shareholders and potential investors are advised to exercise caution.

Link-Asia International Medtech Group Delays Circular Dispatch, Revises Timetable

Link-Asia International Medtech Group Ltd., now known as China Energy Storage Technology Development Limited, is involved in a major transaction concerning the assignment of distribution rights and a proposed rights issue. The company announced a further delay in the dispatch of a circular related to these transactions, pushing the expected date to June 5, 2025. This delay affects the timetable for the rights issue and associated events, potentially impacting shareholder engagement and the company’s strategic initiatives.

China Energy Storage Technology Development Ltd. Announces 2025 AGM

China Energy Storage Technology Development Limited, previously known as Link-Asia International MedTech Group Ltd., has announced its annual general meeting scheduled for June 20, 2025, in Hong Kong. The meeting will address several resolutions including the adoption of the company’s audited accounts for 2024, reappointment of auditors, re-election of executive directors, and authorizing the board to issue additional shares. These resolutions are aimed at strengthening the company’s governance and operational capabilities.

Link-Asia International Medtech Group Delays Circular Dispatch, Revises Timetable

Link-Asia International Medtech Group Ltd., now known as China Energy Storage Technology Development Limited, is involved in a proposed rights issue, change in board lot size, and a major transaction related to the assignment of distribution rights. The company announced a delay in the dispatch of a circular containing details of these proposals, which impacts the expected timetable for these initiatives. The circular is now expected to be dispatched by May 8, 2025, affecting the timeline for shareholder meetings and related activities.